Immutep Making Significant Progress with IMP761 Trial
Media Release
First safety data anticipated before year-end with PK/PD assessments to follow.
Immutep Limited (ASX: IMM; NASDAQ: IMMP), a cutting-edge biotechnology firm, is excited to announce that its Phase I clinical trial of IMP761 has reached a pivotal point. The initial phase of the study, designed to evaluate this innovative LAG-3 immunotherapy, is now fully recruited, and participants have begun receiving the medication without reported safety issues.
From Single Doses to Escalating Findings
The trial, taking place at the Centre for Human Drug Research (CHDR) in the Netherlands, has passed the first stage and is now entering the dose escalation segment. This stage involves administering escalating doses of IMP761 starting at 0.03 mg/kg and potentially reaching up to 0.90 mg/kg for 30 healthy volunteers. The primary focus here will be on both safety and pharmacokinetic (PK) as well as pharmacodynamic (PD) analyses.
Anticipating Enthusiastic Results
As the trial progresses, CHDR will utilize a special model known as the keyhole limpet haemocyanin (KLH) challenge in order to assess the pharmacodynamic activity of IMP761 at this early but critical phase of development. Immutep is optimistic about sharing initial safety data by the end of the year, with further detailed insights regarding PK/PD relationships expected in the first half of the next calendar year.
The Promise of IMP761
IMP761 is a unique first-in-class immunosuppressive LAG-3 agonist antibody, which targets the fundamental causes of various autoimmune diseases. By specifically suppressing memory T cells that accumulate in inflamed tissues, this therapy hopes to restore balance in the immune system.
Exciting Preclinical Findings
Recent preclinical studies highlight the potential of IMP761 to inhibit crucial responses in T cell proliferation and activation, showcasing its promise in managing conditions like oligoarticular juvenile idiopathic arthritis (o-JIA). Results published in notable journals have demonstrated that IMP761 significantly reduces inflammatory responses in just 48 hours for patients suffering from o-JIA, suggesting children with altered LAG-3 metabolism may greatly benefit from this therapy.
About Immutep and Its Vision
Immutep is at the forefront of biotechnology, specializing in the development of innovative therapies centered around LAG-3 mechanisms, aiming to treat both cancer and autoimmune diseases. With a diverse portfolio, the company is committed to advancing treatment options while also maximizing value for its shareholders.
Dedicated Support for Investors and Media
For further inquiries regarding this trial or for media engagement, investors and media representatives are urged to reach out to the respective contacts provided by Immutep. This includes representatives in both Australia and the U.S., who are dedicated to facilitating clear and informative communication regarding ongoing developments.
Frequently Asked Questions
What is the focus of Immutep's IMP761 study?
The study focuses on evaluating IMP761's safety and its pharmacokinetic and pharmacodynamic properties in healthy volunteers.
How does IMP761 work?
IMP761 is designed to suppress autoimmune memory T cells to help restore balance to the immune system, targeting the underlying causes of autoimmune diseases.
What results is Immutep expecting in the trial?
Immutep anticipates the first safety data to be available before the year ends and further PK/PD assessments in the first half of the following year.
Who is leading the clinical trial?
The trial is being conducted by the Centre for Human Drug Research (CHDR) in the Netherlands.
How can I find more information about Immutep?
For more details about Immutep and its ongoing trials, interested parties can visit the official website of Immutep.
